Company / Total Debt
Amphstar Pharmaceuticals, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$619.7M
FY2025
5-year range
$76.6M / $619.7M
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
#26 of 83
Health Care
What the data says
At $620M, Amphstar Pharmaceuticals, Inc.'s total debt ranks #58 of 83 in the Health Care sector. Total Debt has increased for 3 consecutive years, from $77M in FY2022 to $620M in FY2025.
Based on SEC 10-K filings.
$620M in FY2025 with a 5-year CAGR of +68.3%.
Increased from $603M to $620M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +100.7%
- 5-Year CAGR
- +68.3%
- 10-Year CAGR
- -
Sector benchmark
#58 of 83 in Health CareTop 69% of 83This company $619.7M Sector average $6.2B
▼
-89.9% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s total debt has grown for 3 consecutive years.
- 5-year CAGR of +68.3%, indicating consistent growth.
- In FY2025, total debt increased 1.0% year-over-year.
- Ranks #26 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $619.7M | +1.0% |
| FY2024 | $613.5M | +1.7% |
| FY2023 | $603.2M | +687.0% |
| FY2022 | $76.6M | -2.0% |
| FY2021 | $78.2M | +70.3% |
| FY2020 | $45.9M | -0.9% |
| FY2019 | $46.3M | -5.6% |
| FY2018 | $49.1M | +7.4% |
| FY2017 | $45.7M | +26.9% |
| FY2016 | $36.0M | -10.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026